* Annovis Bio Inc ANVS.N ANVS.K is expected to show no
change
in quarterly revenue when it reports results on May 9
(estimated) for the period ending March 31 2024
*
* LSEG's mean analyst estimate for Annovis Bio Inc is for a
loss
of 80 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts had fallen by
about 9.1%
in the last three months.
* Wall Street's median 12-month price target for Annovis Bio
Inc
is $28.00, above its last closing price of $5.39.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT ESTIMATE MET, SE %
E® MISSED
Dec. 31 2023 -1.39 -1.30 -2.24 Missed -71.7
Sep. 30 2023 -1.06 -1.09 -1.63 Missed -49.5
Jun. 30 2023 -1.11 -1.14 -1.07 Beat 6.3
Mar. 31 2023 -0.33 -0.33 -1.19 Missed -256.3
Dec. -1.05 -1.05 -0.38 Beat 63.9
31 2022
Sep. 30 2022 -1.02 -1.01 -0.93 Beat 8.2
Jun. 30 2022 -0.65 -0.64 -1.07 Missed -65.9
Mar. 31 2022 -0.58 -0.58 -0.72 Missed -24.1
This summary was machine generated May 7 at 15:02 GMT. All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)